Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308889 · ClinicalTrials.gov registry record · Early Phase 1
Pro-Resolving Mediators in Acute Inflammation in Humans
A Early Phase 1 study of Blister and Inflammation; Skin, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04308889: Completed Early Phase 1 study of Blister and Inflammation; Skin, sponsored by Brigham and Women's Hospital.
NCT04308889 is a Early Phase 1 study of Blister and Inflammation; Skin that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 19 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04308889, a Early Phase 1 study of Blister and Inflammation; Skin, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.
Primary Outcome
Specialized Pro-Resolving Mediators (SPMs) in a participant's peripheral blood and blister fluid will be extracted and analyzed by targeted metabolo-lipidomics with liquid chromatography - tandem mass spectrometry to identify and quantify SPMs and related bioactive lipid mediators, namely leukotrienes and prostaglandins. Note that these fatty acids and bioactive mediators in blister exudates and peripheral blood will have the same units of measure.
Conditions Studied
Interventions
- OTHER Phlebotomy
- DRUG Lovaza
- OTHER Cantharone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2022-02-22 |
| Phase | Early Phase 1 |
What the finished NCT04308889 record still lists
NCT04308889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Blister appearing as the primary indexed condition, and to 3 interventions - of which Phlebotomy is the first listed.
NCT04308889 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04308889 about?
NCT04308889 is a clinical study titled "Pro-Resolving Mediators in Acute Inflammation in Humans". The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on infl...
What is the current status of trial NCT04308889?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2018-07-02. Estimated completion is 2022-02-22.
What conditions does trial NCT04308889 study?
This clinical trial studies the following conditions: Blister, Inflammation; Skin, Resolution.
What interventions are being tested in trial NCT04308889?
The interventions under investigation include: Phlebotomy (OTHER), Lovaza (DRUG), Cantharone (OTHER).
Who is sponsoring clinical trial NCT04308889?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04308889 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blister
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04308889's enrollment target sits among peer trials
19 1292nd of 2000 higher than 686 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI